Enliven Therapeutics, Inc. - Common Stock (ELVN)

This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical trials.

This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform.

This clinical-stage biotech develops monoclonal antibody therapies targeting psoriasis and other immunology indications.

This Boulder-based biotech, developing targeted cancer therapies, reported a notable insider sale as Phase 1 trials advance for key drug candidates.

The Chief Scientific Officer of this biopharmaceutical company sold 20,000 shares in mid-January 2026, amid the company's stock rising 71% throughout the month.

The company reported positive initial data from its ongoing Phase 1b clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia.

The artificial intelligence landscape, as of December 15, 2025, has been significantly reshaped by the release of Chatterbox Turbo, an advanced open-source text-to-speech (TTS) model developed by Resemble AI. This groundbreaking model promises to democratize high-quality, real-time voice generation, boasting ultra-low latency, state-of-the-art emotional control, and a critical built-in watermarking feature for ethical AI. Its [...]

One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.

This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.

One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch.

Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline?

Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.

Ortex data shows short interest in Enliven Therapeutics had hovered between 24% and 29% since October 2023.

HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant sales potential for Enliven's therapies.

ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.